Scott T. Aaronson, MD

Director, Clinical Research Programs, Sheppard Pratt Health System, Baltimore, Maryland; Director, TMS Services, Sheppard Pratt Health System, Baltimore, Maryland

Scott T. Aaronson, MD, is Director of Clinical Research Programs at Sheppard Pratt Health System in Baltimore, Maryland, where he has been responsible for developing a research program dedicated to the development of medications, devices, and genetic tests for the treatment of illnesses across the spectrum of psychiatric disorders. He is Principal Investigator for studies in various phases and presentations of affective illness and dementia. Dr. Aaronson earned his medical degree with honors from Harvard Medical School in Boston and completed a residency in Psychiatry at McLean Hospital in Belmont, Massachusetts. He is a member of the American College of Psychiatrists.

Dr. Aaronson has published numerous articles on his research in mood disorders and contributed a chapter to a book published this year on Transcranial Magnetic Stimulation by Oxford University Press. Dr. Aaronson is board-certified in Psychiatry and he is a member of several professional organizations, including Distinguished Fellowship in the American Psychiatric Association and the Maryland Psychiatric Society for which he currently serves as President. He also serves as Chairman of the Data Safety and Management Board for the Maryland Psychiatric Research Center.